secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001386570-25-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth
--------------------------------------------------------------------------------

- Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.
- Gross margin improved 480 bps to 65.0%; adjusted EBITDA $5.0M, up 221%.
- Raises FY2025 revenue growth outlook to 22%-27% (previously 20%-25%).
- Secured exclusive worldwide license for Niagen in Parkinson's therapy; NOPARK Phase III trial dosing completed, data expected 2026.
- Niagen Plus available in 800+ U.S. wellness clinics (up from 475 in Dec 2024); cash $60.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000011/0001386570-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000011/cdxc-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001386570-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer